
Last updated: 2026-09-08 08:40:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Acurx Pharmaceuticals, Inc. (ACXP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.42, with a market capitalization of $6.10M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.31 to $8.34. This page covers its latest market performance, valuation, price trends and company information.
$6.10M | |
$1.40 | |
$176.40 | |
$1.31 | |
$1.40 | |
47.00K | |
122.86K | |
-- | |
$8.34 | |
$1.31 | |
-- | |
-- |
Acurx Pharmaceuticals, Inc. (ACXP) is trading at $1.42 in pre-market trading as of 2026-09-04 21:06:00, up 1.07% ($0.02) from the previous close of $1.40
Pre-market trading shows how investors are pricing ACXP before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Acurx Pharmaceuticals, Inc. (ACXP) moved from $1.46 to $1.42, representing a decline of 3.08% ($0.04).
The stock traded between $1.38 and $1.48 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 79.97 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.5%
ACXP is currently trading at $1.42, placing it 1.5% of the way from its 52-week low of $1.31 to its 52-week high of $8.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Acurx Pharmaceuticals, Inc. (ACXP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.